The stock of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) is a huge mover today! The stock increased 4.46% or $0.95 on November 23, hitting $22.25. About 364,856 shares traded hands. Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has risen 24.93% since April 22, 2016 and is uptrending. It has outperformed by 19.52% the S&P500.
The move comes after 6 months positive chart setup for the $1.05B company. It was reported on Nov, 24 by Barchart.com. We have $23.59 PT which if reached, will make NASDAQ:SUPN worth $63.00M more.
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Ratings Coverage
Out of 3 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Supernus Pharmaceuticals has been the topic of 6 analyst reports since August 26, 2015 according to StockzIntelligence Inc. The firm has “Neutral” rating by Piper Jaffray given on Monday, July 18. The stock has “Outperform” rating given by Northland Capital on Thursday, November 5. Northland Capital initiated Supernus Pharmaceuticals Inc (NASDAQ:SUPN) on Wednesday, October 28 with “Outperform” rating. The firm earned “Buy” rating on Thursday, August 4 by Jefferies. As per Monday, July 18, the company rating was downgraded by Northland Capital. The stock has “Hold” rating given by Zacks on Wednesday, August 26.
According to Zacks Investment Research, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.”
Insitutional Activity: The institutional sentiment decreased to 1.04 in Q2 2016. Its down 0.22, from 1.26 in 2016Q1. The ratio turned negative, as 27 funds sold all Supernus Pharmaceuticals Inc shares owned while 62 reduced positions. 25 funds bought stakes while 87 increased positions. They now own 45.62 million shares or 4.54% more from 43.64 million shares in 2016Q1.
Moreover, Cubist Systematic Strategies Lc has 0.01% invested in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) for 12,480 shares. Farmers & Merchants reported 334 shares or 0% of all its holdings. Prudential holds 0.01% or 197,656 shares in its portfolio. Employees Retirement Sys Of Texas, a Texas-based fund reported 28,000 shares. Renaissance Group Inc Ltd Liability last reported 0.01% of its portfolio in the stock. Aqr Cap Mgmt Ltd Llc holds 0.01% or 149,156 shares in its portfolio. Shell Asset Management holds 0.03% of its portfolio in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) for 57,411 shares. Meeder Asset Incorporated last reported 2,307 shares in the company. Rice Hall James & Limited has 0.64% invested in the company for 543,606 shares. Moreover, Ftb Advsr has 0% invested in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) for 554 shares. Mgmt Corp Va holds 0.28% or 35,630 shares in its portfolio. Blackrock has invested 0% of its portfolio in Supernus Pharmaceuticals Inc (NASDAQ:SUPN). Moreover, Dana Advisors has 0.09% invested in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) for 104,257 shares. Blackrock Fund Advsr holds 0.01% or 3.10 million shares in its portfolio. Diam Limited owns 24,840 shares or 0.01% of their US portfolio.
Insider Transactions: Since September 16, 2016, the stock had 0 buys, and 1 sale for $50,000 net activity. 2,000 shares with value of $50,000 were sold by PATRICK GREGORY S on Friday, September 16.
Another recent and important Supernus Pharmaceuticals Inc (NASDAQ:SUPN) news was published by Investorplace.com which published an article titled: “Supernus Pharmaceuticals Inc (SUPN) Stock Dips Despite Positive ADHD Data” on October 11, 2016.
SUPN Company Profile
Supernus Pharmaceuticals, Inc. (Supernus), incorporated on March 30, 2005, is a pharmaceutical firm focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Firm offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It is also engaged in developing multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD). The Company’s psychiatry product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). It is also developing SPN-810 as a treatment for IA in patients who have ADHD and SPN-812 for the treatment of ADHD. It is also developing SPN-809 (viloxazine hydrochloride) for the treatment of depression. The Firm markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.